Vitality Watch

Dossier pubmed preclinical 10-sep-2026
Animal model, organoid, or cell-culture result — not yet human

Bazi Bushen attenuates musculoskeletal degeneration in Ercc1mice.

Key claim: Bazi Bushen ameliorates age-related muscle atrophy and bone loss in Ercc1-deficient progeroid mice while reducing senescence markers and restoring endocrine balance.

Abstract

BACKGROUND: Age-related musculoskeletal degeneration, characterized by the coexistence of sarcopenia and osteoporosis, represents a growing health burden among older adults. Current therapeutic strategies generally target either skeletal muscle or bone, and few are designed to address both tissues. METHODS: Female wild-type (WT) and Ercc1mice were assigned to four groups (n = 6 per group): WT controls, untreated Ercc1mice, and Ercc1mice treated with nicotinamide mononucleotide (NMN; 300 mg/kg/day) or Bazi Bushen (BZBS; 2 g/kg/day). Body composition, skeletal muscle mass, and grip strength were assessed, while bone microarchitecture and femoral mechanical properties were evaluated using micro-computed tomography (micro-CT) and three-point bending tests, respectively. Histomorphological changes in skeletal muscle and femur were assessed using hematoxylin and eosin (H&E), Masson’s trichrome, and Goldner’s trichrome staining. The expression levels of the senescence-associated proteins p16 and p21 and the atrophy-related proteins Atrogin-1 and MuRF-1 were determined by Western blotting. Indirect calorimetry was used to assess whole-body energy metabolism. Serum levels of estradiol (E2), follicle-stimulating hormone (FSH), and myostatin were measured by ELISA. RESULTS: Ercc1mice exhibited reduced lean mass and grip strength, skeletal muscle fiber atrophy with increased collagen deposition, impaired bone microarchitecture, and impaired femoral mechanical properties. BZBS treatment significantly ameliorated these abnormalities in skeletal muscle and bone and reduced the expression of p16, p21, Atrogin-1, and MuRF-1 in skeletal muscle. In addition, BZBS increased whole-body energy metabolism and spontaneous locomotor activity, lowered serum levels of myostatin and FSH, and increased serum estradiol levels. CONCLUSION: BZBS improved skeletal muscle mass and function, trabecular bone microarchitecture, and bone mechanical properties in female Ercc1mice and reduced the skeletal muscle expression of proteins associated with atrophy and senescence. These improvements may be associated with increased whole-body energy metabolism and spontaneous locomotor activity, as well as lower circulating levels of myostatin and FSH and higher levels of E2. These findings provide preclinical support for further investigation of BZBS as a potential multisystem intervention for age-related musculoskeletal degeneration.

Why this matters

[animal-model] This study adds a dual muscle-and-bone outcome signal for Bazi Bushen to the preclinical TCM intervention landscape, with accompanying changes in senescence and endocrine measures. [animal-model] Its accelerated-aging mouse model leaves translation to ordinary human aging unresolved, and reduced senescence markers do not by themselves establish senolytic activity.

Source

Link

Briefing card

Bazi Bushen attenuates musculoskeletal degeneration in Ercc1mice.
Stage: preclinical · pubmed · 10-sep-2026

If you take Bazi Bushen for muscle or bone health, this finding reports benefits in accelerated-aging mice, not demonstrated benefits in humans.

Bazi Bushen ameliorates age-related muscle atrophy and bone loss in Ercc1-deficient progeroid mice while reducing senescence markers and restoring endocrine balance.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.exger.2026.113314

build build 880 · 2bcef25 · 2026-11-18